Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Arance

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006G V Long, A Arance, L Mortier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialJ Guo, R D Carvajal, R Dummer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic MelanomaA Arance, M-A Berciano-Guerrero, J Guo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2026
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanomaJ C Hassel, A Arance, M S Carlino, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 6, 2017
Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access ProgramM González-Cao, A Arance, J M Piulats, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanomaY J L Jansen, E A Rozeman, R Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer typesL Paré, T Pascual, E Seguí, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines CommitteeO Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines CommitteeU Keilholz, P A Ascierto, R Dummer, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2021
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006G V Long, A Arance, L Mortier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialJ Guo, R D Carvajal, R Dummer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic MelanomaA Arance, M-A Berciano-Guerrero, J Guo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 23, 2026
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanomaJ C Hassel, A Arance, M S Carlino, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 6, 2017
Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access ProgramM González-Cao, A Arance, J M Piulats, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanomaY J L Jansen, E A Rozeman, R Mason, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer typesL Paré, T Pascual, E Seguí, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 6, 2017
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 studyG V Long, K T Flaherty, D Stroyakovskiy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines CommitteeO Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines CommitteeU Keilholz, P A Ascierto, R Dummer, et al.
Pageof 4